NO325020B1 - Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett - Google Patents
Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett Download PDFInfo
- Publication number
- NO325020B1 NO325020B1 NO20001273A NO20001273A NO325020B1 NO 325020 B1 NO325020 B1 NO 325020B1 NO 20001273 A NO20001273 A NO 20001273A NO 20001273 A NO20001273 A NO 20001273A NO 325020 B1 NO325020 B1 NO 325020B1
- Authority
- NO
- Norway
- Prior art keywords
- bnp
- antibody
- mammalian
- derivatives
- immunoassay
- Prior art date
Links
- 238000004458 analytical method Methods 0.000 title description 23
- 238000003018 immunoassay Methods 0.000 claims abstract description 23
- 108010080850 prepro-brain natriuretic peptide Proteins 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 57
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 57
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 55
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 55
- 238000000034 method Methods 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000005259 measurement Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 13
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 12
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 12
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 208000019622 heart disease Diseases 0.000 description 11
- 206010019280 Heart failures Diseases 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001452 natriuretic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020001621 Natriuretic Peptide Proteins 0.000 description 3
- 102000004571 Natriuretic peptide Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000692 natriuretic peptide Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101500026746 Canis lupus familiaris Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24668497 | 1997-09-11 | ||
| PCT/JP1998/004063 WO1999013331A1 (fr) | 1997-09-11 | 1998-09-10 | Procede de dosage immunologique pour bnp |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20001273D0 NO20001273D0 (no) | 2000-03-10 |
| NO20001273L NO20001273L (no) | 2000-05-10 |
| NO325020B1 true NO325020B1 (no) | 2008-01-14 |
Family
ID=17152093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001273A NO325020B1 (no) | 1997-09-11 | 2000-03-10 | Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6828107B2 (de) |
| EP (1) | EP1016867B1 (de) |
| JP (1) | JP3516655B2 (de) |
| KR (1) | KR100563358B1 (de) |
| CN (1) | CN1161609C (de) |
| AT (1) | ATE315228T1 (de) |
| AU (1) | AU731858B2 (de) |
| CA (1) | CA2304263C (de) |
| DE (1) | DE69833118T2 (de) |
| DK (1) | DK1016867T3 (de) |
| ES (1) | ES2256952T3 (de) |
| NO (1) | NO325020B1 (de) |
| WO (1) | WO1999013331A1 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
| US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US7524635B2 (en) | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
| US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
| US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
| EP1419388B1 (de) * | 2001-08-20 | 2009-10-07 | Biosite Incorporated | Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon |
| US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
| US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
| JP3691803B2 (ja) * | 2002-03-14 | 2005-09-07 | 三洋化成工業株式会社 | 血液中の心不全マーカー定量方法 |
| AUPS169202A0 (en) * | 2002-04-11 | 2002-05-16 | Goetze, Jens Peter | Neuropeptide assay |
| JP4514606B2 (ja) | 2002-05-09 | 2010-07-28 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | 心血管疾患マーカーおよび治療標的としてのｉｌ１ｒｌ−１ |
| FR2843396B1 (fr) * | 2002-08-07 | 2005-04-15 | Bio Rad Pasteur | Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque |
| US7135329B2 (en) * | 2002-11-18 | 2006-11-14 | Princeton Biomeditech Corporation | Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients |
| US7109023B2 (en) * | 2002-11-18 | 2006-09-19 | Princeton Biomeditech Corporation | Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients |
| EP1638443B1 (de) * | 2003-06-20 | 2010-10-20 | Mayo Foundation For Medical Education And Research | Isoformen von gehirn-natriuretischem peptid |
| JP2007525213A (ja) * | 2004-01-27 | 2007-09-06 | コンピュゲン ユーエスエイ，インク． | 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法 |
| US20080182299A1 (en) * | 2004-01-27 | 2008-07-31 | Compugent Ltd. | Novel brain natriuretic peptide variants and methods of use thereof |
| ES2352845T3 (es) * | 2004-03-19 | 2011-02-23 | BIOMEDICA MEDIZINPRODUKTE GMBH & CO KG | Métodos de pronóstico para la insuficiencia cardiaca congestiva. |
| AT500800B1 (de) * | 2004-09-08 | 2008-07-15 | Biomedica Medizinprodukte Gmbh | Verfahren zur bestimmung von probnp |
| EP1794588A2 (de) * | 2004-09-09 | 2007-06-13 | Biosite Incorporated | Verfahren und zusammensetzungen zur messung von hunde-bnp und verwendungen davon |
| US7731965B2 (en) | 2005-02-17 | 2010-06-08 | Abbott Lab | Human ring specific BNP antibodies |
| US7939069B2 (en) | 2005-11-09 | 2011-05-10 | Abbott Laboratories | Human BNP immunospecific antibodies |
| CA2629438C (en) | 2005-11-09 | 2014-02-25 | Abbott Laboratories | Human bnp immunospecific antibodies |
| ES2351623T3 (es) | 2006-04-24 | 2011-02-08 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de una enfermedad grave. |
| ES2380711T3 (es) | 2006-05-01 | 2012-05-17 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedades cardiovasculares |
| CN101501067B (zh) * | 2006-08-08 | 2013-01-16 | 梅约医学教育与研究基金会 | 利尿和利尿钠的多肽 |
| US20080064045A1 (en) | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
| US20080108147A1 (en) * | 2006-11-03 | 2008-05-08 | Tie Wei | Reduction of non-specific binding in immunoassays |
| WO2008095046A2 (en) | 2007-01-30 | 2008-08-07 | Loma Vista Medical, Inc., | Biological navigation device |
| AT504942B1 (de) | 2007-03-07 | 2009-08-15 | Biomedica Medizinprodukte Gmbh | Verfahren zur bestimmung von probnp |
| FI20075251A0 (fi) * | 2007-04-13 | 2007-04-13 | Hytest Oy | Immunomääritys epästabiilien antigeenien määrittämiseksi |
| US20080280377A1 (en) * | 2007-05-08 | 2008-11-13 | Abbott Laboratories | Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms |
| WO2009036448A2 (en) * | 2007-09-15 | 2009-03-19 | Mayo Foundation For Medical Education And Research | Natriuretic peptide receptor-c agonists |
| WO2009086126A2 (en) * | 2007-12-21 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| SI3093663T1 (sl) | 2008-04-18 | 2018-10-30 | Critical Care Diagnostics, Inc. | Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov |
| US20090299327A1 (en) | 2008-06-02 | 2009-12-03 | Lorna Vista Medical, Inc. | Inflatable medical devices |
| WO2010077654A1 (en) * | 2008-12-08 | 2010-07-08 | Biosite Incorporated | Combined natriuretic peptide assays |
| CN101923090A (zh) * | 2009-06-10 | 2010-12-22 | 中国科学院电子学研究所 | 固定人体脑钠肽的光学敏感膜的制备方法 |
| WO2012009486A2 (en) | 2010-07-13 | 2012-01-19 | Loma Vista Medical, Inc. | Inflatable medical devices |
| CA2807240A1 (en) | 2010-08-04 | 2012-02-09 | Idexx Laboratories, Inc. | Detection of degradation products of canine nt-probnp |
| US10188436B2 (en) | 2010-11-09 | 2019-01-29 | Loma Vista Medical, Inc. | Inflatable medical devices |
| AU2012262154B2 (en) | 2011-05-31 | 2016-08-04 | Idexx Laboratories, Inc. | Detection of degradation products of feline NT-proBNP |
| JP2014525439A (ja) | 2011-08-30 | 2014-09-29 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | ナトリウム利尿ポリペプチド |
| US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
| MX2015002254A (es) | 2012-08-21 | 2015-05-08 | Critical Care Diagnostics Inc | Estratificacion de riesgo para marcador multiple. |
| CN112710852B (zh) * | 2021-03-26 | 2021-08-03 | 上海美迪西生物医药股份有限公司 | 一种gnp多肽的检测试剂盒及检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2676114B2 (ja) * | 1990-04-16 | 1997-11-12 | 塩野義製薬株式会社 | ｈＢＮＰを認識するモノクローナル抗体および該抗体を用いるｈＢＮＰの免疫測定法 |
| GB9211686D0 (en) * | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
-
1998
- 1998-09-10 US US09/508,435 patent/US6828107B2/en not_active Expired - Lifetime
- 1998-09-10 DE DE69833118T patent/DE69833118T2/de not_active Expired - Lifetime
- 1998-09-10 CN CNB988110539A patent/CN1161609C/zh not_active Expired - Fee Related
- 1998-09-10 EP EP98941797A patent/EP1016867B1/de not_active Expired - Lifetime
- 1998-09-10 DK DK98941797T patent/DK1016867T3/da active
- 1998-09-10 JP JP2000511064A patent/JP3516655B2/ja not_active Expired - Fee Related
- 1998-09-10 WO PCT/JP1998/004063 patent/WO1999013331A1/ja active IP Right Grant
- 1998-09-10 AU AU90010/98A patent/AU731858B2/en not_active Ceased
- 1998-09-10 KR KR1020007002530A patent/KR100563358B1/ko not_active IP Right Cessation
- 1998-09-10 AT AT98941797T patent/ATE315228T1/de not_active IP Right Cessation
- 1998-09-10 CA CA002304263A patent/CA2304263C/en not_active Expired - Fee Related
- 1998-09-10 ES ES98941797T patent/ES2256952T3/es not_active Expired - Lifetime
-
2000
- 2000-03-10 NO NO20001273A patent/NO325020B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69833118T2 (de) | 2006-08-31 |
| CN1278919A (zh) | 2001-01-03 |
| EP1016867A4 (de) | 2004-11-17 |
| CN1161609C (zh) | 2004-08-11 |
| KR100563358B1 (ko) | 2006-03-22 |
| CA2304263C (en) | 2008-07-29 |
| US6828107B2 (en) | 2004-12-07 |
| AU9001098A (en) | 1999-03-29 |
| ES2256952T3 (es) | 2006-07-16 |
| CA2304263A1 (en) | 1999-03-18 |
| KR20010023853A (ko) | 2001-03-26 |
| DK1016867T3 (da) | 2006-05-22 |
| EP1016867B1 (de) | 2006-01-04 |
| NO20001273D0 (no) | 2000-03-10 |
| ATE315228T1 (de) | 2006-02-15 |
| DE69833118D1 (de) | 2006-03-30 |
| US20030157596A1 (en) | 2003-08-21 |
| EP1016867A1 (de) | 2000-07-05 |
| WO1999013331A1 (fr) | 1999-03-18 |
| AU731858B2 (en) | 2001-04-05 |
| JP3516655B2 (ja) | 2004-04-05 |
| NO20001273L (no) | 2000-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325020B1 (no) | Immunanalyse som er spesifikk for pattedyr-gamma-BNP-derivater samt sett | |
| Struck et al. | Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients | |
| JP4932714B2 (ja) | コペプチンを使用する疾患の診断方法 | |
| Belenky et al. | The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma | |
| US7534582B2 (en) | Method for measuring the amount of natriuretic peptides in a sample | |
| US20130157311A1 (en) | Methods of Determination of Activation or inactivation of Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) Hormonal Systems | |
| US20100028921A1 (en) | Risk stratification for acute coronary syndrome by means of fragments/partial peptides of provasopressin, especially copeptin or neurophysin ii | |
| ES2271674T3 (es) | Inmunoensayo tipo sandwich para la determinacion de peptidos parciales proanp. | |
| JP2005510234A (ja) | ポリペプチドの定量 | |
| EP1816477A1 (de) | Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen | |
| JP5734547B2 (ja) | 生物学的液体中のナトリウム利尿ペプチドのサンプリングのための方法、組成物、および装置 | |
| Wijbenga et al. | Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice | |
| JP4294961B2 (ja) | 試料中の実効的な副甲状腺ホルモン活性の測定方法 | |
| Vesely et al. | Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and β2-microglobulin in patients with congestive heart failure | |
| Jüppner et al. | Radioimmunoassay for human osteocalcin using an antibody raised against the synthetic human (h37–49) sequence | |
| Špinarová et al. | Prognostic impact of copeptin and mid-regional pro-adrenomedullin in chronic heart failure with regard to comorbidities | |
| US7226729B1 (en) | Method for inhibiting degradation of brain natriuretic peptides | |
| Erfurt et al. | Secretion of Prohormone of B-Type Natriuretic Peptide, proBNP1-108, Is Increased in Heart Failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |